iRadimed Corporation Common Stock (IRMD)

FairStock Score: 54/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am looking for a small but durable business with honest accounting, high returns, and a price that leaves room for error. iRadimed fits part of that: it sells MRI-compatible infusion pumps and monitoring systems, a narrow niche where hospitals need reliability. The filed record is attractive. In fiscal 2025, the year ended 2025-12-31, revenue was $83.8M, net income $22.5M, and diluted EPS $1.75. In fiscal 2024, ended 2024-12-31, revenue was $73.2M, net income $19.2M, and EPS $1.50; in fiscal 2023, ended 2023-12-31, revenue was $65.6M, net income $17.2M, and EPS $1.35. FairStock calculations at the 2026-10-13 close show ROE 23.52%, ROCE 15.56%, and Altman Z 54.03, signs of profitability and balance-sheet safety. But the latest quarter, ended 2026-06-30, showed revenue of $20.5M, net income of $5.2M, and diluted EPS of $0.41, versus revenue of $20.4M, net income of $5.8M, and EPS of $0.45 in the quarter ended 2025-06-30. Sales barely moved and profit fell. The FairStock Lynch category labels it a FAST GROWER from five-year profit growth of 75.0% a year and revenue growth of 21.5%, yet current results are soft. At the 2026-10-13 close, the FairStock P/E is 50.08, P/B 11.26, EV/EBITDA 37.26, FCF yield 2.1%, and Graham Number $17.90 with margin of safety -400.84%. That is no bargain. The business is good; the price already assumes a brisk recovery.

In plain English: iRadimed makes special pumps and monitors that work safely inside MRI machines. The business has been profitable and generates a lot of profit for each dollar invested, but its most recent quarter showed almost no sales growth and lower profit. At the recent price, the stock looks expensive relative to current profits, cash flow, and accounting value, so the price seems to assume stronger growth ahead.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K/A (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer